Mutational Status and Clinical Outcomes Following Systemic Therapy with or without Focal Radiation for Resected Melanoma Brain Metastases

• Published in: World neurosurgery Vol. 170; pp. e514 - e519
• Main Authors: Vasudevan, Harish N., Susko, Matthew S., Ma, Lijun, Nakamura, Jean L., Raleigh, David R., Boreta, Lauren, Fogh, Shannon, Theodosopoulos, Philip V., McDermott, Michael W., Tsai, Katy K., Sneed, Penny K., Braunstein, Steve E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-02-2023
• Subjects: BRAF; Brain Neoplasms - genetics; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Focal radiation; Humans; Immunotherapy; Melanoma - drug therapy; Melanoma - therapy; Melanoma brain metastases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf - genetics; Radiosurgery; Radiosurgery - methods; Retrospective Studies; Systemic therapy; Focal radiation; OS; MRI; CI; Radiosurgery; Melanoma brain metastases; CNS; BRAF; IQR; Systemic therapy; ARE; SRS; Immunotherapy; PFS
• ISSN: 1878-8750; 1878-8769; 1878-8769
• DOI: 10.1016/j.wneu.2022.11.060

Brain metastases occur frequently in advanced melanoma and traditionally require surgery and radiation therapy. New evidence demonstrates that systemic therapies are effective for controlling metastatic melanoma brain metastases. This study evaluated outcomes after resection of melanoma brain metastases treated with systemic therapy, with or without focal radiotherapy.
All patients received immunotherapy or BRAF/MEK inhibitors preoperatively or in the immediate 3 months postoperatively. Resection cavity failure, distant central nervous system progression, and adverse radiation effects were reported in the presence and absence of focal radiotherapy using the Kaplan-Meier method.
Between 2011 and 2020, 37 resection cavities in 29 patients met criteria for analysis. Of lesions, 22 (59%) were treated with focal radiotherapy, and 15 (41%) were treated with targeted therapy or immunotherapy alone. The 12- and 24-month freedom from local recurrence was 64.8% (95% confidence interval [CI] 42.1%–99.8%) and 46.3% (95% CI 24.5%–87.5%), respectively, for systemic therapy alone and 93.3% (95% CI 81.5%–100%) at both time points for focal radiotherapy (P = 0.01). On univariate analysis, focal radiotherapy was the only significant factor associated with reduction of local recurrence risk (hazard ratio 0.10, 95% CI 0.01–0.85; P = 0.04). There were no significant differences in central nervous system progression-free survival or overall survival between patients who received systemic therapy plus focal radiotherapy compared with systemic therapy alone. BRAF mutation status was reviewed for either the brain metastasis (n = 9 patients, 31%) or the primary site (n = 20 patients, 69%), and patients harboring BRAFV600E mutations had worse progression-free survival (P = 0.043).
Focal radiotherapy with systemic therapy for resected melanoma brain metastases significantly decreased resection cavity recurrence compared with systemic therapy alone. BRAF mutation status correlated with poorer outcomes.